EconPapers    
Economics at your fingertips  
 

Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Martina Garau, Grace Hampson (), Nancy Devlin (), Nicola Amedeo Mazzanti and Antonio Profico
Additional contact information
Nicola Amedeo Mazzanti: Roche S.P.A
Antonio Profico: Roche S.P.A

PharmacoEconomics - Open, 2018, vol. 2, issue 2, 153-163

Abstract: Abstract Background Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders’ preferences and be explicit about the trade-offs that are being made. Objective The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL). Methods We used EVIDEM V3.0, an MCDA framework, and collected participants’ preferences via an online survey and structured meetings. Results Patients and clinicians expressed a preference for interventions targeting severe conditions. Payers expressed preference for treatments targeting areas with an unmet need, which are cheaper than the comparator, and with high-quality evidence. Obinutuzumab in combination with bendamustine, compared with bendamustine alone, received high positive scores for the criteria ‘disease severity’ and ‘type of therapeutic benefit’ by all three groups, and negative scores on the economic-related criteria, according to all stakeholder groups. Conclusions MCDA can be used to elicit the views of different stakeholder groups and has the potential to structure and inform reimbursement decisions.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed

Downloads: (external link)
http://link.springer.com/10.1007/s41669-017-0048-x Abstract (text/html)

Related works:
Working Paper: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (2016) Downloads
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0048-x

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla ().

 
Page updated 2019-11-06
Handle: RePEc:spr:pharmo:v:2:y:2018:i:2:d:10.1007_s41669-017-0048-x